Bladder Cancer, Muscle-invasive Bladder Cancer
Conditions
Keywords
pegfilgrastim, MVAC
Brief summary
The purpose of this research study is to test the effectiveness of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) in combination with pegfilgrastim followed by radical surgery in patients with muscle-invasive urothelial carcinoma.
Detailed description
* Participants will be given a study infusion schedule for each treatment cycle. Each treatment cycle lasts three weeks. The infusion of methotrexate will take place on the first day of each cycle. Infusions of vinblastine, doxorubicin and cisplatin will take place on the second day and an injection of pegfilgrastim will be given on the third day. * During all treatment cycles participants will have a physical exam and will be asked questions about their general health and any problems they might be having and any medications they may be taking. * Following completion of study treatment, but before surgery, participants will have an assessment of their tumor by CT scan of the chest and and MRI of the abdomen and pelvis. * Following the participants surgery, we would like to keep track of their medical condition indefinitely, or until this study is officially completed. We would like to do this by calling the participants on the telephone once a year to see how they are doing.
Interventions
DRUGMethotrexate
intravenously 30mg/m2 over 30 minutes
DRUGDoxorubicin
intravenously 30mg/ms over 15 minutes
DRUGvinblastine
intravenously 3mg/m2 over 30 minutes
DRUGcisplatin
intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion
DRUGPegfilgrastim
Given subcutaneously 24 hours after last chemotherapy dose
Sponsors
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Amgen
Dana-Farber Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologic proof of urothelial cancer. Patients with all histologic subtypes are eligible as long as transitional cell carcinoma is predominant, with the exception of more than a few clusters of small cell carcinoma, which is treated with different chemotherapy and thus are ineligible * Patients with primary tumors arising in the bladder or urethra are eligible if they have clinical T2-T4a disease * Patients with primary tumors arising in the ureter or renal pelvis are eligible if they have either grade 3 tumors, or radiographic abnormality large enough to be recognized as an abnormal mass by CT/imaging * Evaluation by a urologist and be deemed to be acceptable surgical candidates within 3 months of registration * Adequate physiologic reserves as outlined in the protocol * Clinical or pathologic N1 lymph node involvement (involvement of a single lymph node \< 2cm in greatest dimension) are eligible. Patients with N2-3 or M1 disease are ineligible * Determination of LV function with an EF \> 50% * Women of child-bearing potential must have a negative pregnancy test * Patients of child-bearing or father-bearing potential must agree to use an acceptable form of birth control while on the study * Patients with prior malignancy are eligible provided that the expected outcome from the prior cancer is such that this will not interfere in the delivery of this therapy, or the assessment of response in the cystectomy specimen * 18 years of age or older
Exclusion criteria
* Current, recent (within 3 weeks), or planned participation with other experimental anti-cancer medications as part of clinical trials * Prior treatment with doxorubicin * Prior systemic cytoreductive chemotherapy for bladder cancer * Blood pressure of \> 160/100 mmHg. Patients whose blood pressure can be controlled with oral medication are eligible * NYHA Grade II or greater congestive heart failure * History of myocardial infarction or unstable angina within 6 months prior to study enrollment * History of stroke or transient ischemic attack within 6 months prior to study enrollment * Clinically significant peripheral vascular disease * Evidence of bleeding diathesis or coagulopathy * Known history of central nervous system or brain metastases * Major surgical procedure, significant traumatic injury within 21 days prior to Day 1, or anticipation of need for major surgical procedure during the course of the study * Lactating women * Patients who are not candidates for surgery, or unwilling to undergo surgery * Patients with significant fluid collection * Known hypersensitivity to any component of cisplatin, methotrexate, vinblastine, doxorubicin or pegfilgrastim
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients Achieving Pathologic Response | After completion of 4 cycles of chemotherapy with pegfilgrastim support (cycle length 2 weeks) | Pathological response is defined as down-staging to \</=pT1, N0 after chemotherapy with pegfilgrastim support. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients Experiencing Febrile Neutropenia | After completion of 4 cycles of chemotherapy with pegfilgrastim support (cycle length 2 weeks) | Febrile neutropenia defined per CTCAEv3 as Grade 3 or higher and treatment attribution possibly, probably or definitely-related. |
| Number of Patients Experiencing Surgery-related Toxicity | Surgery + 30 days | Surgery-related toxicity defined per CTCAEv3 as Grade 2 or higher and treatment attribution possibly, probably or definitely-related. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dose Dense MVAC Methotrexate: intravenously 30mg/m2 over 30 minutes
Doxorubicin: intravenously 30mg/ms over 15 minutes
vinblastine: intravenously 3mg/m2 over 30 minutes
cisplatin: intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion
Pegfilgrastim: Given subcutaneously 24 hours after last chemotherapy dose | 39 |
| Total | 39 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Disease progression before surgery. | 1 |
Baseline characteristics
| Characteristic | Dose Dense MVAC |
|---|---|
| Age, Continuous | 57 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 39 Participants |
| Region of Enrollment United States | 39 participants |
| Sex: Female, Male Female | 11 Participants |
| Sex: Female, Male Male | 28 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 32 / 39 |
| serious Total, serious adverse events | 4 / 39 |
Outcome results
Primary
Number of Patients Achieving Pathologic Response
Pathological response is defined as down-staging to \</=pT1, N0 after chemotherapy with pegfilgrastim support.
Time frame: After completion of 4 cycles of chemotherapy with pegfilgrastim support (cycle length 2 weeks)
Population: Analysis population consists of all enrolled patients.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dose Dense MVAC | Number of Patients Achieving Pathologic Response | 49 percentage of pathologic responders |
Comparison: This study used a Simon's optimal two-stage design. Of 39 eligible patients, if 18 achieved PaR, the treatment would be declared effective. A two-sided 80% CI was estimated considering the two-stage design based on Atkinson and Brown methods.80% CI: [38, 61]
Secondary
Number of Patients Experiencing Febrile Neutropenia
Febrile neutropenia defined per CTCAEv3 as Grade 3 or higher and treatment attribution possibly, probably or definitely-related.
Time frame: After completion of 4 cycles of chemotherapy with pegfilgrastim support (cycle length 2 weeks)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dose Dense MVAC | Number of Patients Experiencing Febrile Neutropenia | 0 participants |
Secondary
Number of Patients Experiencing Surgery-related Toxicity
Surgery-related toxicity defined per CTCAEv3 as Grade 2 or higher and treatment attribution possibly, probably or definitely-related.
Time frame: Surgery + 30 days
Population: Number of patients who underwent cystectomy.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dose Dense MVAC | Number of Patients Experiencing Surgery-related Toxicity | 4 participants |